Evidence map›Paper›PMID 24944315›Full record

ReviewClinical cancer research : an official journal of the American Association for Cancer Research2014

Prostate cancer SubtyPINg biomarKers and outcome: is clarity emERGing?

Steven C Smith, Scott A Tomlins

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical cancer research : an official journal of the American Association for Cancer Research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Steven C SmithDepartment of Pathology, Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, Michigan. Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
Scott A TomlinsDepartment of Pathology, Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, Michigan. Department of Urology, Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan. Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan. tomlinss@umich.edu.

Funding

Exploiting drivers of androgen receptor signaling negative prostate cancer for prR01CA183857 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI TOMLINS, SCOTT A · 2014 to 2018
$1.6M
NCI NIH HHS R01 CA183857NCI NIH HHS R01-CA-183857-01
6 · The paper itself

Abstract

Molecular prostate cancer subtypes have been proposed on the basis of mutually exclusive SPINK1 and ERG overexpression, with conflicting reports on their prognostic ability. Flavin and colleagues report that SPINK1 is neither prognostic nor absolutely mutually exclusive with ERG, raising important questions about prostate cancer molecular subtyping and prognostic biomarker evaluation.

Indexed as

Prostatic NeoplasmsBiomarkers, TumorCarrier ProteinsHumansMalePrognosisTrans-ActivatorsTranscriptional Regulator ERGTrypsin Inhibitor, Kazal PancreaticBiomarkers, TumorCarrier ProteinsERG protein, humanSPINK1 protein, humanTrans-ActivatorsTranscriptional Regulator ERGTrypsin Inhibitor, Kazal Pancreatic

Identifiers

PMID24944315
PMCPMC4167216

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.